Two in One: Europe Clears First Dual Respiratory Shot

Europe approves Moderna’s mCOMBRIAX, the first single-dose vaccine targeting both flu and COVID-19 for adults aged 50 and up

28 May 2026

Regulatory history was made on April 21, 2026, when the European Commission granted marketing authorization to Moderna’s mCOMBRIAX, the first single vaccine approved globally to target both seasonal influenza and COVID-19. The clearance is valid across all 27 European Union member states, as well as Iceland, Liechtenstein, and Norway. According to company statements, the authorization covers adults aged 50 and older, a demographic disproportionately vulnerable to winter respiratory pathogens.

Built on messenger RNA technology, the combination vaccine encodes instructions for protection against three seasonal influenza strains alongside the SARS-CoV-2 virus in a single formulation. Data from a pivotal Phase 3 clinical trial involving 8,000 participants demonstrated that the combination shot elicited immune responses that met or exceeded those produced by separately administered flu and COVID-19 vaccines. Following a comprehensive review of these data, an expert committee of the European Medicines Agency issued a positive recommendation in February, paving the way for the final executive decision.

Public health officials have long struggled with declining vaccination rates, noting that seasonal flu shot uptake across Europe consistently falls short of targets for older populations. European public health agencies suggested that consolidating two distinct, annually recommended injections into a single appointment could directly reduce the immunization burden on patients and clinics. Moderna executives said that the dual-target formulation aims to simplify seasonal delivery while reinforcing healthcare systems against simultaneous winter surges.

Still, the commercial landscape for the vaccine remains complex as the broader sector shifts away from pandemic-era purchasing models. Analysts noted that while European authorization establishes a clear precedent, uptake will depend entirely on individual national regulatory bodies and reimbursement procedures, which vary widely across the continent. The decision also highlights an emerging regulatory divide, following a series of separate evaluation standards set by the United States Food and Drug Administration for alternative components of the company's respiratory portfolio.

The decision positions messenger RNA technology as a permanent fixture of public health infrastructure rather than a temporary crisis response. For the commercial sector, the milestone carries deep financial weight, given that European markets account for roughly one-third of global mRNA vaccine revenues. As the single-shot framework rolls out, the results could shape international immunization policies and manufacturing strategies in the years ahead.